Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Oxonica was a nanotechnology company that developed and commercialized engineered nanomaterials for the healthcare, personal care, and energy sectors. Spun out from the University of Oxford in 1999, the company became a leader in the application of nanoparticles to solve industrial and medical challenges. Its healthcare division focused on Surface Enhanced Raman Spectroscopy (SERS) technology, which enabled the development of highly sensitive diagnostic tests for various biomarkers. The company's most notable products included Optisol, an advanced UV filter for sunscreens, and Envirox, a fuel-borne catalyst designed to improve fuel economy. Following a period of commercial growth and a public listing on the London Stock Exchange's AIM, the company's diagnostics business was acquired by Becton, Dickinson and Company (BD) in 2010.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Oxonica.